Cognition Therapeutics, Inc.
Harrison, NY
- UEI
- NUNHAKQ7MS86
- CAGE
- 5CQK3
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 2500 Westchester Ave, Purchase, NY 10577, USA
- Website
- cogrx.com
- Founded
- 2007
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Industrials
- Commercial & Professional Services
- Professional Services
- Research & Consulting Services
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Virogenics, Inc. | San Diego, CA | 238990 All Other Specialty Trade Contractors |
| T3D Therapeutics, Inc. | Durham, NC | — |
| Bolden Therapeutics Inc. | Providence, RI | — |
| Oligomerix Inc. | NY | — |
| Adrx, Inc. | Thousand Oaks, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Cognition Therapeutics, Inc. is a clinical stage neuroscience company developing small molecule therapeutics to treat age-related degenerative diseases of the central nervous system and retina. Through prime federal grant awards from the National Institutes of Health, mainly the National Institute on Aging, Cognition Therapeutics has conducted research to develop and test CT1812, an investigational therapy for Alzheimer's disease and other neurodegenerative conditions. Projects have included clinical trials evaluating CT1812 safety and efficacy in Alzheimer's disease patients, an absorption/metabolism/excretion study in healthy volunteers, and a pilot electroencephalography study on CT1812's effect on synaptic activity. Additional grants support extending CT1812 evaluation to other indications like dementia with Lewy bodies. In total, Cognition Therapeutics has been awarded over $150 million to advance CT1812 through preclinical and clinical phases.
Quick answers
Is Cognition Therapeutics, Inc. registered in SAM.gov?
Yes. Cognition Therapeutics, Inc.'s SAM.gov registration is active through March 11, 2027.
What is Cognition Therapeutics, Inc.'s most recent federal award?
Cognition Therapeutics, Inc.'s most recent federal grant award is A randomized, double-blind, placebo-controlled, parallel-group, phase 2 study to evaluate the safety and efficacy of… (R01AG071643), from National Institute on Aging (NIH), on May 15, 2021.
On GovTribe
See Cognition Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors